KR20170084086A - 오나프리스톤 연장-방출 조성물 및 방법 - Google Patents

오나프리스톤 연장-방출 조성물 및 방법 Download PDF

Info

Publication number
KR20170084086A
KR20170084086A KR1020177012909A KR20177012909A KR20170084086A KR 20170084086 A KR20170084086 A KR 20170084086A KR 1020177012909 A KR1020177012909 A KR 1020177012909A KR 20177012909 A KR20177012909 A KR 20177012909A KR 20170084086 A KR20170084086 A KR 20170084086A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
extended release
onapristone
formulation
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177012909A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 주키브스키
스테판 프로니크
Original Assignee
아르노 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르노 테라퓨틱스 인코포레이티드 filed Critical 아르노 테라퓨틱스 인코포레이티드
Publication of KR20170084086A publication Critical patent/KR20170084086A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177012909A 2014-11-17 2015-11-16 오나프리스톤 연장-방출 조성물 및 방법 Ceased KR20170084086A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080868P 2014-11-17 2014-11-17
US62/080,868 2014-11-17
PCT/US2015/060940 WO2016081383A1 (en) 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods

Publications (1)

Publication Number Publication Date
KR20170084086A true KR20170084086A (ko) 2017-07-19

Family

ID=56014429

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012909A Ceased KR20170084086A (ko) 2014-11-17 2015-11-16 오나프리스톤 연장-방출 조성물 및 방법

Country Status (11)

Country Link
US (3) US10786461B2 (OSRAM)
EP (1) EP3247362A4 (OSRAM)
JP (1) JP6655075B2 (OSRAM)
KR (1) KR20170084086A (OSRAM)
CN (2) CN106999501B (OSRAM)
AU (2) AU2015350241B2 (OSRAM)
CA (1) CA2966753A1 (OSRAM)
HK (1) HK1246653A1 (OSRAM)
MX (1) MX391191B (OSRAM)
RU (1) RU2017112748A (OSRAM)
WO (1) WO2016081383A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3321826A1 (de) 1983-06-15 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
ES8502612A1 (es) 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
US4742000A (en) 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
DE3630030A1 (de) 1986-09-01 1988-03-03 Schering Ag 13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5283190A (en) 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
DE4008584A1 (de) 1990-03-15 1991-09-26 Schering Ag Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
CN1053450C (zh) 1992-11-19 2000-06-14 北京第三制药厂 17位取代11β－取代芳香基－4,9－雌甾二烯类化合物的全合成法
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ZA959008B (en) * 1994-10-24 1996-09-16 Schering Ag Competitive progesterone antagonists for demand-oriented female birth control
US5759577A (en) 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
US5962444A (en) 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
UY26966A1 (es) 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
US7381976B2 (en) 2001-03-13 2008-06-03 Triton Thalassic Technologies, Inc. Monochromatic fluid treatment systems
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US7105642B2 (en) 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
US20040121304A1 (en) 2001-12-21 2004-06-24 Ulrike Fuhrmann Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
WO2004078709A2 (en) 2003-02-28 2004-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
ES2360806T3 (es) 2004-07-09 2011-06-09 The Population Council, Inc. Composiciones de liberación prolongada que contienen moduladores de receptores de progesterona.
AU2005289728B2 (en) 2004-09-22 2011-11-24 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
WO2006111856A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
EP2021499A4 (en) 2005-12-16 2010-02-17 Univ Leland Stanford Junior FUNCTIONAL ARRAYS FOR THE IDENTIFICATION OF ELEMENTS FOR GENE PRESSION REGULATION WITH HIGH THROUGHPUT
US20070167971A1 (en) 2006-01-17 2007-07-19 Raymond Huey Devices and methods for promoting the formation of blood clots in esophageal varices
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
PL1989217T4 (pl) 2006-02-17 2013-02-28 Janssen Pharmaceutica Nv 11-fosforowe pochodne steroidowe użyteczne jako modulatory receptora progesteronu
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
CN101668739A (zh) 2007-04-24 2010-03-10 帝斯曼知识产权资产管理有限公司 用于制造前维生素d的光化学方法
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
AR068986A1 (es) * 2007-10-12 2009-12-23 Novartis Ag Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2009100258A1 (en) 2008-02-05 2009-08-13 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical solid state forms
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TW201002736A (en) 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
WO2010110086A1 (ja) 2009-03-27 2010-09-30 株式会社小松製作所 作業車両の省燃費制御装置および作業車両の省燃費制御方法
US9074002B2 (en) 2009-04-27 2015-07-07 Cold Spring Harbor Laboratory PTP1B inhibitors
US20110003753A1 (en) 2009-06-01 2011-01-06 Samuel Waxman Cancer Research Foundation COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER
MX2012000680A (es) 2009-07-15 2012-02-28 S Bio Pte Ltd Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno.
US20110293511A1 (en) 2009-09-29 2011-12-01 Terrance Grant Johns Specific binding proteins and uses thereof
US8261855B2 (en) * 2009-11-11 2012-09-11 Flanders Electric, Ltd. Methods and systems for drilling boreholes
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
SG183924A1 (en) * 2010-03-22 2012-10-30 Repros Therapeutics Inc Compositions and methods for non-toxic delivery of antiprogestins
WO2012087983A1 (en) 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2638163B1 (en) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-associated non-coding rnas
US20140018404A1 (en) 2010-12-16 2014-01-16 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
JP2014510080A (ja) 2011-03-09 2014-04-24 セントローズ， エルエルシー 細胞外標的化薬物複合体
JP6118273B2 (ja) 2011-03-11 2017-04-19 セルジーン コーポレイション 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用
ES2656988T3 (es) 2011-04-15 2018-03-01 J-Pharma Co., Ltd. Biomarcador para el cáncer de mama
AU2012258087B2 (en) 2011-05-13 2017-07-20 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
WO2013052652A1 (en) 2011-10-04 2013-04-11 Erard Gilles Methods and systems for identifying and treating anti-progestin sensitive tumors
BR112014013709A2 (pt) 2011-12-08 2017-08-22 Fund Sales Métodos, composições farmaceuticas, e kits, para tratar cânceres resitentes às antiprogestinas
US20130338016A1 (en) 2012-04-17 2013-12-19 Vala Sciences, Inc. Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
AU2013252913A1 (en) 2012-04-27 2014-11-27 Regents Of The University Of Minnesota Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
EP2877210A4 (en) 2012-07-24 2016-06-29 Cedars Sinai Medical Center A NEW METHOD FOR DETECTING THE RESISTANCE TO CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER
US20150320795A1 (en) 2012-12-13 2015-11-12 Roy JOSEE Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
CA2904116C (en) * 2013-03-12 2021-09-14 Arno Therapeutics Onapristone polymorphic forms and methods of use
US20140363425A1 (en) 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CN103483449A (zh) 2013-08-20 2014-01-01 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
US20150285803A1 (en) 2014-04-08 2015-10-08 Invivis Pharmaceuticals Inc. Systems and methods for identifying progesterone receptor subtypes
HK1246653A1 (zh) 2014-11-17 2018-09-14 Context Biopharma Inc. 奥那司酮延长释放组合物和方法
AU2016235298B2 (en) 2015-03-23 2021-03-11 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
JP2019513706A (ja) 2016-03-21 2019-05-30 コンテキスト・バイオファーマ・インコーポレイテッド オナプリストン代謝物質組成物及び方法
WO2017192567A1 (en) 2016-05-02 2017-11-09 Tetragenetics, Inc. ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF
WO2018067198A1 (en) 2016-10-03 2018-04-12 The Regents Of The University Of California Inhibitory antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP3247362A4 (en) 2018-10-10
AU2015350241B2 (en) 2021-05-20
CA2966753A1 (en) 2016-05-26
US20210220279A1 (en) 2021-07-22
CN106999501B (zh) 2021-08-13
EP3247362A1 (en) 2017-11-29
MX391191B (es) 2025-03-21
CN106999501A (zh) 2017-08-01
RU2017112748A3 (OSRAM) 2019-06-26
US20160166583A1 (en) 2016-06-16
RU2017112748A (ru) 2018-12-19
JP2017537883A (ja) 2017-12-21
US11672762B2 (en) 2023-06-13
WO2016081383A1 (en) 2016-05-26
HK1246653A1 (zh) 2018-09-14
AU2015350241A1 (en) 2017-05-04
CN113559075A (zh) 2021-10-29
US20230157960A1 (en) 2023-05-25
US10786461B2 (en) 2020-09-29
JP6655075B2 (ja) 2020-02-26
MX2017005163A (es) 2018-01-18
AU2021218093A1 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
US20230157960A1 (en) Onapristone extended-release compositions and methods
JP7667132B2 (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
TW201410247A (zh) 醫藥組合
EP3863618A1 (en) Methods of treating cancer with pi3k alpha inhibitors and metformin
KR20200013602A (ko) 세균성 질증의 치료에 사용하기 위한 세크니다졸
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US11083722B2 (en) Combination therapies for the treatment of breast cancer
TW202133857A (zh) 用於乳癌治療之組合療法
KR20120000579A (ko) 간세포 암종의 치료방법
US20250235451A1 (en) Methods of Delaying Pain Progression And Treating Prostate Cancer
WO2024165068A1 (zh) 取代2-氢-吡唑衍生物的联用药物组合物及其用途
CN114340625B (zh) 用雌激素受体-α抑制剂的口服剂型治疗癌症的方法
EP4301356A1 (en) Treatment of breast cancer with amcenestrant and palbociclib
HK40062842A (en) Onapristone extended-release compositions and methods
CN112535688A (zh) 药物组合
CN114533886B (zh) 一种用于晚期乳腺癌治疗的药物组合物
US20240165078A1 (en) Therapeutic targeting of receptor tyrosine kinase inhibitor-induced androgen receptor phosphorylation in cancer
TW202444376A (zh) 治療癌症之方法
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
EP4547248A1 (en) Anti-angiogenic therapy as treatment for benign uterine disorders
CN118660706A (zh) Cdk4和6抑制剂与氟维司群组合用于在cdk4和6抑制剂先前治疗的患者中治疗激素受体阳性、人表皮生长因子受体2阴性晚期或转移性乳腺癌
TW202400136A (zh) 以安森司群(amcenestrant)治療乳癌
CN118804747A (zh) 用安森司群治疗乳腺癌
TW202342044A (zh) Cdk4及6抑制劑及氟維司群用於治療先前以cdk4及6抑制劑治療的患者之荷爾蒙受體陽性、人類表皮生長因子受體2陰性之晚期或轉移性乳癌

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20180822

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201105

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230703

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230912

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230703

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I